REGENXBIO Inc.
RGNXREGENXBIO Inc. (RGNX) is a biotechnology company specializing in the development and commercialization of gene therapy treatments. Founded in 2013, it focuses on leveraging its proprietary NAV Technology platform to create novel therapeutic options for a range of genetic, neurovascular, and retinal diseases. The company's goal is to advance gene therapy science and deliver transformative treatments to patients.
Company News
The choroidal neovascularization therapeutics market is projected to grow significantly between 2025-2034, driven by rising AMD prevalence, technological advancements, and emerging gene therapies targeting vision preservation.
The global viral vector gene therapy market is projected to grow from $13.14 billion in 2024 to $38.39 billion by 2034, driven by advancements in vector design, increasing genetic disease prevalence, and strong R&D investments.
The Duchenne muscular dystrophy market is experiencing steady growth driven by advancements in gene therapies, exon-skipping drugs, and emerging treatment options. Key players are expanding pipelines with novel therapies in late-stage clinical trials, with potential market transformation expected between 2025-2034.
Coave Therapeutics, a company pioneering genetic medicines, has established a new Scientific Advisory Board (SAB) with renowned experts in AAV vector biology, gene therapy for ophthalmology and CNS diseases, and extra-hepatic gene delivery. The SAB will provide strategic guidance to support Coave's R&D initiatives and the development of its ALIGA...
The report provides a comprehensive analysis of the Adeno-Associated Virus (AAV) Vectors in Gene Therapy pipeline, highlighting the potential of this technology to revolutionize the treatment of genetic disorders. It examines the challenges in scalable production and safety, as well as the industry's focus on optimizing vectors for improved safet...
